Physician profile
Peter Lorber
NPI 1902961501
$868.41
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $94.53.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $400.68 | 2019 | |
| Mdd US Operations, LLC | $102.18 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $87.31 | 2019 | |
| Amneal Pharmaceuticals LLC | $65.24 | 2019 | |
| Acorda Therapeutics, INC | $47.32 | 2019 | |
| Vertical Pharmaceuticals, LLC | $46.60 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $36.43 | 2019 | |
| Alexion Pharmaceuticals, INC. | $32.07 | 2019 | |
| Abbott Laboratories | $31.52 | 2019 | |
| Allergan, INC. | $19.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lorber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.